Q-omics provides the consensus-scored BDKRB2 profile across patient tissues and cancer cell-line models. BDKRB2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BDKRB2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, BDKRB2 RNA expression shows 17,191 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where BDKRB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BDKRB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BDKRB2 survival associations across molecular data types. BDKRB2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BDKRB2 RNA expression–survival associations across cancer types. High BDKRB2 expression shows unfavorable associations in UVM, KIRP, ACC, LGG and BLCA, but favorable associations in KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for BDKRB2 RNA expression.
This table summarizes BDKRB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BDKRB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BDKRB2 shows lower tumor expression in KIRC, KIRP, BLCA, THCA, KICH and COAD. The KIRC box plot shows higher BDKRB2 RNA expression in normal versus tumor tissue (log2 FC = −1.983, t-test p < 0.001).
This table shows molecular features associated with BDKRB2 in patient tissues and cancer cell lines. In patient samples, BDKRB2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BDKRB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
